Comparison · NCT02540954-sae
Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks): serious adverse events. Trial comparisons, record NCT02540954-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02540954-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.156 | 0.109 | 0.218 | wilson | |
| Risk in group 2 | 0.137 | 0.093 | 0.197 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0188 | -0.0577 | 0.0953 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.677 | 1.91 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 0.634 | 2.13 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Aflibercept Extended Dosing than on Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | 53.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Aflibercept Extended Dosing | Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed). | 26 | 167 | EG000 |
| Group 2 | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed. | 23 | 168 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From after the first application of aflibercept in the study to 30 days after the last dose of study drug over approximately 1.5 years.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- NCT number
- NCT02540954
- Phases
- PHASE3
- Conditions
- Macular Degeneration
- Interventions
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Lead sponsor
- Bayer
- Results first posted
- 2021-04-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02540954?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02540954-sae